Travere Therapeutics (TVTX) Enterprise Value (2016 - 2025)
Travere Therapeutics (TVTX) has disclosed Enterprise Value for 13 consecutive years, with -$93.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 58.94% year-over-year to -$93.0 million, compared with a TTM value of -$93.0 million through Dec 2025, down 58.94%, and an annual FY2025 reading of -$93.0 million, down 58.94% over the prior year.
- Enterprise Value was -$93.0 million for Q4 2025 at Travere Therapeutics, up from -$110.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$32.3 million in Q2 2024 and bottomed at -$256.6 million in Q1 2022.
- Average Enterprise Value over 5 years is -$97.1 million, with a median of -$68.5 million recorded in 2025.
- The sharpest move saw Enterprise Value skyrocketed 74.76% in 2024, then crashed 204.68% in 2025.
- Year by year, Enterprise Value stood at -$165.8 million in 2021, then soared by 62.78% to -$61.7 million in 2022, then rose by 5.69% to -$58.2 million in 2023, then fell by 0.62% to -$58.5 million in 2024, then tumbled by 58.94% to -$93.0 million in 2025.
- Business Quant data shows Enterprise Value for TVTX at -$93.0 million in Q4 2025, -$110.9 million in Q3 2025, and -$75.2 million in Q2 2025.